• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床尿液药物检测中的“假阳性”和“假阴性”检测结果。

'False-positive' and 'false-negative' test results in clinical urine drug testing.

作者信息

Reisfield Gary M, Goldberger Bruce A, Bertholf Roger L

机构信息

Department of Community Health and Family Medicine, University of Florida College of Medicine, 655 West 8th Street, Jacksonville, FL 32209, USA.

出版信息

Bioanalysis. 2009 Aug;1(5):937-52. doi: 10.4155/bio.09.81.

DOI:10.4155/bio.09.81
PMID:21083064
Abstract

The terms 'false-positive' and 'false-negative' are widely used in discussions of urine drug test (UDT) results. These terms are inadequate because they are used in different ways by physicians and laboratory professionals and they are too narrow to encompass the larger universe of potentially misleading, inappropriate and unexpected drug test results. This larger universe, while not solely comprised of technically 'true' or 'false' positive or negative test results, presents comparable interpretive challenges with corresponding clinical implications. In this review, we propose the terms 'potentially inappropriate' positive or negative test results in reference to UDT results that are ambiguous or unexpected and subject to misinterpretation. Causes of potentially inappropriate positive UDT results include in vivo metabolic conversions of a drug, exposure to nonillicit sources of a drug and laboratory error. Causes of potentially inappropriate negative UDT results include limited assay specificity, absence of drug in the urine, presence of drug in the urine, but below established assay cutoff, specimen manipulation and laboratory error. Clinical UDT interpretation is a complicated task requiring knowledge of recent prescription, over-the-counter and herbal drug administration, drug metabolism and analytical sensitivities and specificities.

摘要

“假阳性”和“假阴性”这两个术语在尿液药物检测(UDT)结果的讨论中被广泛使用。但这些术语并不恰当,因为医生和实验室专业人员对它们的使用方式不同,而且它们过于狭窄,无法涵盖潜在的误导性、不恰当和意外的药物检测结果的更大范畴。这个更大的范畴虽然不完全由技术上“真”或“假”的阳性或阴性检测结果组成,但也带来了类似的解释挑战以及相应的临床意义。在本综述中,我们针对UDT结果中模糊、意外且易被误解的情况,提出了“潜在不恰当”的阳性或阴性检测结果这一术语。潜在不恰当的阳性UDT结果的原因包括药物的体内代谢转化、接触非非法来源的药物以及实验室误差。潜在不恰当的阴性UDT结果的原因包括检测方法特异性有限、尿液中无药物、尿液中有药物但低于既定检测下限、样本处理以及实验室误差。临床UDT解读是一项复杂的任务,需要了解近期的处方用药、非处方用药和草药用药情况、药物代谢以及分析灵敏度和特异性。

相似文献

1
'False-positive' and 'false-negative' test results in clinical urine drug testing.临床尿液药物检测中的“假阳性”和“假阴性”检测结果。
Bioanalysis. 2009 Aug;1(5):937-52. doi: 10.4155/bio.09.81.
2
Rational use and interpretation of urine drug testing in chronic opioid therapy.慢性阿片类药物治疗中尿液药物检测的合理应用与解读
Ann Clin Lab Sci. 2007 Autumn;37(4):301-14.
3
Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients.比较免疫分析法与液相色谱串联质谱法(LC/MS/MS)尿液药物检测(UDT)在慢性疼痛患者中检测阿片类药物和非法药物的准确性。
Pain Physician. 2011 Mar-Apr;14(2):175-87.
4
[On-site testing for drug abuse in urine].[尿液中药物滥用的现场检测]
Tidsskr Nor Laegeforen. 2006 Sep 7;126(17):2257-60.
5
Results of random drug testing in an adolescent substance abuse program.青少年药物滥用项目中的随机药物检测结果。
Pediatrics. 2007 Apr;119(4):e843-8. doi: 10.1542/peds.2006-2278.
6
Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).慢性疼痛患者即时检测(POC)或门诊尿液药物检测(免疫测定)准确性的方案:免疫测定和液相色谱串联质谱法(LC/MS/MS)的前瞻性分析。
Pain Physician. 2010 Jan-Feb;13(1):E1-E22.
7
Mechanism of interferences for gas chromatography/mass spectrometry analysis of urine for drugs of abuse.用于滥用药物尿液气相色谱/质谱分析的干扰机制。
Ann Clin Lab Sci. 1995 Jul-Aug;25(4):319-29.
8
Lower Cutoffs for LC-MS/MS Urine Drug Testing Indicates Better Patient Compliance.尿液药物检测 LC-MS/MS 下限降低表明患者的依从性更好。
Pain Physician. 2017 Nov;20(7):E1107-E1113.
9
Urine drug screening: a valuable office procedure.尿液药物筛查:一项有价值的门诊程序。
Am Fam Physician. 2010 Mar 1;81(5):635-40.
10
Interferences with urine drug screens.尿液药物筛查的干扰因素。
J Pharm Pract. 2011 Feb;24(1):102-8. doi: 10.1177/0897190010380463. Epub 2010 Nov 22.

引用本文的文献

1
Urine Drug Screening as Adjunct to History Taking During Intake in Addiction Services.成瘾服务机构入院时,尿液药物筛查作为病史采集的辅助手段
Indian J Psychol Med. 2024 Jan;46(1):88-89. doi: 10.1177/02537176231184598. Epub 2023 Jul 18.
2
Acute opioid overdose in pediatric patients.小儿患者急性阿片类药物过量
J Am Coll Emerg Physicians Open. 2024 Mar 7;5(2):e13134. doi: 10.1002/emp2.13134. eCollection 2024 Apr.
3
Prevalence of xylazine among people who inject drugs seeking medical care at a syringe services program clinic: Miami, Florida, 2023.
2023年佛罗里达州迈阿密一家注射器服务项目诊所中寻求医疗护理的注射吸毒者中赛拉嗪的流行情况。
Drug Alcohol Depend Rep. 2023 Dec 5;9:100209. doi: 10.1016/j.dadr.2023.100209. eCollection 2023 Dec.
4
Immunoassay Urine Drug Testing among Patients Receiving Opioids at a Safety-Net Palliative Medicine Clinic.在一家安全网姑息医学诊所接受阿片类药物治疗的患者中进行免疫分析尿液药物检测。
Cancers (Basel). 2023 Nov 30;15(23):5663. doi: 10.3390/cancers15235663.
5
A Review of Drug Abuse, Misuse, and Related Laboratory Challenges.药物滥用、误用及相关实验室挑战综述
Curr Drug Saf. 2024;19(4):417-430. doi: 10.2174/0115748863266621231023112044.
6
Prevention of drug diversion and substance use disorders among anesthesiologists: a narrative review.预防麻醉师药物滥用和物质使用障碍:叙述性综述。
Braz J Anesthesiol. 2023 Nov-Dec;73(6):810-818. doi: 10.1016/j.bjane.2023.07.008. Epub 2023 Jul 28.
7
Bridging the gap: The critical role of laboratory developed tests in clinical toxicology.弥合差距:实验室自建检测在临床毒理学中的关键作用。
J Mass Spectrom Adv Clin Lab. 2023 Feb 22;28:70-74. doi: 10.1016/j.jmsacl.2023.02.007. eCollection 2023 Apr.
8
Opioids in Hemodialysis Patients.血液透析患者中的阿片类药物。
Semin Nephrol. 2021 Jan;41(1):24-32. doi: 10.1016/j.semnephrol.2021.02.003.
9
COVID-19 and Substance Use Disorders: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine Practice and Policy Interest Group Position Paper.2019冠状病毒病与物质使用障碍:全面医疗应对建议。国际成瘾医学学会实践与政策兴趣小组立场文件
Basic Clin Neurosci. 2020 Mar-Apr;11(2):133-150. doi: 10.32598/bcn.11.covid19.1. Epub 2020 Apr 12.
10
Urine drug screens: Considerations for the psychiatric pharmacist.尿液药物筛查:精神科药剂师的考量因素
Ment Health Clin. 2016 Mar 8;6(1):42-47. doi: 10.9740/mhc.2016.01.042. eCollection 2016 Jan.